Skip to main content
Premium Trial:

Request an Annual Quote

Lucence Taps Omnigen to Distribute Liquid Biopsy Tests in Turkey

NEW YORK – Precision oncology firm Lucence said Tuesday that it has entered a new partnership with laboratory diagnostics distributor Omnigen Medical Products to expand access to its liquid biopsy tests for cancer patients in Turkey.

Under the terms of the agreement, Omnigen will market tests, including Lucence's LiquidHallmark next-generation sequencing assay, to Turkish hospitals and clinicians as part of its existing business as a distributor of genetic testing and molecular and pathological equipment.

According to Lucence — which is headquartered in Palo Alto, California, with additional offices in Singapore and China — tests will be performed in its CLIA-certified, CAP-accredited laboratories.

Financial terms of the deal were not disclosed.

The company highlighted that LiquidHallmark has been extensively validated in breast and colorectal cancers, which are the most common malignancies in the region.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.